AUS
NZ
UK
CA
USA
IND
Highlights
- Advanced Diagnostic Tool: Promarker®D predicts chronic kidney disease up to four years in advance.
- Nationwide Availability: Initial rollout in Western Australia and the Northern Territory, with plans to expand across Australia.
- Global Expansion: A new Reference Laboratory in California sets the stage for entry into the USA and European markets.
Proteomics International Laboratories (ASX:PIQ) has taken a significant step in diabetes care with the official launch of Promarker®D in Australia. This predictive test is designed to identify the risk of chronic kidney disease in individuals with type 2 diabetes, allowing for earlier intervention and improved patient outcomes.
Addressing a Growing Health Concern
With over 1.3 million Australians diagnosed with diabetes, kidney disease remains a major health challenge. More than half of these individuals are at risk of developing chronic kidney complications, which can lead to severe conditions such as kidney failure and the need for dialysis. The introduction of Promarker®D aims to change this trajectory by providing early warnings—up to four years in advance—so that healthcare providers can take proactive measures.
Expanding Access Across Australia
Initially, the test will be available to healthcare professionals in Western Australia and the Northern Territory. Following this regional launch, Proteomics International Laboratories (ASX:PIQ) plans to expand access to healthcare providers nationwide. This strategic rollout ensures that patients across Australia benefit from this innovative diagnostic technology.
Setting the Stage for Global Reach
The Australian launch marks a critical milestone in the company’s broader international strategy. To support expansion into key global markets, Proteomics International Laboratories (ASX:PIQ) has established a Reference Laboratory in California. This facility will play a vital role in bringing Promarker®D to the USA and Europe, where the burden of diabetes-related kidney disease is also a pressing concern.
A Step Forward in Early Detection
The introduction of Promarker®D aligns with global efforts to enhance early detection and management of chronic diseases. By offering an advanced predictive tool, Proteomics International Laboratories (ASX:PIQ) is contributing to a future where diabetes patients can receive timely care, reducing complications and improving quality of life.
On the occasion of World Kidney Day, the company’s Managing Director, Dr. Richard Lipscombe, emphasized the importance of early diagnosis, stating that Promarker®D provides a highly accurate and accessible solution to identify individuals most at risk. The test not only helps in managing personal health but also reduces the economic burden associated with diabetes-related kidney disease.
As healthcare systems increasingly prioritize preventative medicine, innovations like Promarker®D represent a shift toward more proactive and personalized patient care, reinforcing the commitment to tackling chronic illnesses with cutting-edge technology.
